NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...
These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...
Although current pulse-oximetry technology cannot detect every cardiac defect, the rate of missed CCHD diagnoses is much higher when screening is based on physical examination alone. Health-care ...
is a senior reporter and author of the Optimizer newsletter. She has more than 13 years of experience reporting on wearables, health tech, and more. Before coming to The Verge, she worked for Gizmodo ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub. The first application of ...
These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results